Skip to content

Sanofi SA Price, Chart & Factor Exposure

Free Data & Analytics Access

Next earnings: Thu, Jan 28, 2027, after the market closes · estimates and history

Sanofi SA · E.SAN.PA · France
Use symbol E.SAN.PA in our API & Excel add-in to retrieve this data ↓
80.63
(+0.01%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 50%
Trend 75%
Bubble Risk LOW
Realised Volatility (20D) 24.29%

Sanofi SA Forecast

Sanofi SA short-term momentum is positive (up over 3 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (7 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 24.3% a year, a typical one-standard-deviation range is 77.87–83.39 over a week, 74.98–86.28 over a month and 61.05–100.21 over a year. (Signals as of 5 Nov 2026.)

Sanofi SA Price Chart

MacroFinance.ai
Market/MacroIndicatorNowChangeRange
Quantitative
Sanofi SA
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Sanofi SA
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Sanofi SA
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
Sanofi SA
P/E
13.86x
Mid-range vs own history
QoQ −0.8%
YoY +21.0%
now 13.86398.5 low15.06 high
ⓘP/E As of 22 Nov 2026.See Sanofi SA returns when P/E looked like now →Opens Return analysis with the filter P/E within ±5% of today
Sanofi SA
P/S
1.93x
Cheap vs own history
QoQ −1.8%
YoY −16.7%
now 1.9321.7 low2.3 high
ⓘP/S As of 22 Nov 2026.See Sanofi SA returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
Sanofi SA
P/B
1.33x
Cheap vs own history
QoQ −2.7%
YoY −8.7%
now 1.32761.17 low1.44 high
ⓘP/B As of 22 Nov 2026.See Sanofi SA returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
Sanofi SA
EV/EBITDA
8.52x
Mid-range vs own history
QoQ −6.9%
YoY +0.2%
now 8.51897.61 low10.1 high
ⓘEV/EBITDA As of 22 Nov 2026.See Sanofi SA returns when EV/EBITDA looked like now →Opens Return analysis with the filter EV/EBITDA within ±5% of today
Sanofi SA
EV/Sales
2.21x
Cheap vs own history
QoQ −5.0%
YoY −15.0%
now 2.20921.97 low2.58 high
ⓘEV/Sales As of 22 Nov 2026.See Sanofi SA returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
Sanofi SA
FCF Yield
15.6%
Mid-range vs own history
QoQ −0.2%
YoY +13.7%
now 15.631113.65 low17.8 high
ⓘFCF Yield As of 22 Nov 2026.See Sanofi SA returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
Sanofi SA
Earnings Yield
7.2%
Mid-range vs own history
QoQ +0.8%
YoY −17.4%
now 7.2136.64 low11.77 high
ⓘEarnings Yield As of 22 Nov 2026.See Sanofi SA returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
Sanofi SA
Market Cap
$96.8B
Lowest in 5 years
QoQ +2.4%
YoY −9.2%
now 9675684,972 low105,819 high
ⓘMarket Cap As of 22 Nov 2026.See Sanofi SA returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
Sanofi SA
Net Debt
$13.9B
Mid-range vs own history
QoQ −19.4%
YoY +8.0%
now 1387912,849 low17,226 high
ⓘNet Debt As of 22 Nov 2026.See Sanofi SA returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
Sanofi SA
Net Debt / EBITDA
1.07x
Mid-range vs own history
QoQ −24.3%
YoY +16.8%
now 1.06870.91 low1.41 high
ⓘNet Debt / EBITDA As of 22 Nov 2026.See Sanofi SA returns when Net Debt / EBITDA looked like now →Opens Return analysis with the filter Net Debt / EBITDA within ±5% of today
Sanofi SA
Current Ratio
1.12x
Mid-range vs own history
QoQ +13.0%
YoY +5.2%
now 1.11560.99 low1.12 high
ⓘCurrent Ratio As of 22 Nov 2026.See Sanofi SA returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
Sanofi SA
Quick Ratio
0.27x
Mid-range vs own history
QoQ +18.6%
YoY −7.5%
now 0.27490.22 low0.73 high
ⓘQuick Ratio As of 22 Nov 2026.See Sanofi SA returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
Sanofi SA
Interest Coverage
11.53x
Mid-range vs own history
QoQ +9.0%
YoY +2.1%
now 11.532110.58 low14.86 high
ⓘInterest Coverage As of 22 Nov 2026.See Sanofi SA returns when Interest Coverage looked like now →Opens Return analysis with the filter Interest Coverage within ±5% of today
Sanofi SA
Debt / Equity
0.27x
Mid-range vs own history
QoQ −20.1%
YoY −8.3%
now 0.27230.27 low0.34 high
ⓘDebt / Equity As of 22 Nov 2026.See Sanofi SA returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
Sanofi SA
Piotroski F-Score
8
Mid-range vs own history
QoQ +33.3%
YoY −11.1%
now 86 low8 high
ⓘPiotroski F-Score As of 22 Nov 2026.See Sanofi SA returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
  18 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  16 members-only factors: Sloan Accruals, Cash-Earnings Gap, Beneish M-Score, Days Sales in Receivables Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for Sanofi SA, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Sanofi SA fundamentals: income statement, balance sheet & cash flow

Sanofi SA reported revenue of €46.72bn and net income of €7.81bn in FY2025, the year ended 31 December 2025 — revenue up 5.5% and net income up 40.5% on the prior year. Free cash flow was €8.99bn. These figures are as reported in the filings, not restated: 27 fiscal years and 98 quarters of history, back to December 1999.

Revenue (FY2025)
€46.72bn
+5.5%
Net income
€7.81bn
+40.5%
Gross margin
72.07%
Free cash flow
€8.99bn
+52.7%
Net debt
€12.94bn
Sanofi SA income statement, annual, as reported · EUR billions unless stated
EUR billionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue46.7244.2941.1140.3039.18
Cost of revenue13.0513.2012.6211.8712.25
Gross profit33.6731.0928.4928.4426.92
Research & development7.847.396.516.505.69
Selling, general & admin.—9.18———
Operating income9.6014.4512.9813.158.13
EBITDA12.4812.4612.5513.4911.70
Interest expense0.630.600.520.390.36
Pre-tax income6.026.766.129.997.84
Income tax1.041.201.021.911.56
Net income7.815.565.408.376.22

Download Sanofi SA fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.SAN.PA&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks all 27 fiscal years and 98 quarters, the filing vintages behind each number and API access.
Create free account

Figures in EUR, statements as filed. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic.

Research on Sanofi SA

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Sanofi SA Trading Strategies

9 backtested tactical asset allocation strategies hold VGK (European market), the closest tradable exposure to Sanofi SA; 1 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

Explore all strategies →

Statistical Distribution of Returns

Plus

How Sanofi SA’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Sanofi SA behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Sanofi SA (France)

Sanofi SA is a listed security in France. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

More on Banco Santander

Frequently asked questions

What is Sanofi SA?
Sanofi SA is a listed security in France. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Sanofi SA price?
The latest close is 80.63 (5 Nov 2026), +0.01% on the day. The price at the top of the page refreshes during the trading day.
Is Sanofi SA in an uptrend?
As of 5 Nov 2026, short-term momentum is positive (3 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly positive (7 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Sanofi SA?
20-day realised volatility is 24.3% a year (5 Nov 2026), which implies a typical one-standard-deviation move of about 7.0% over a month and 3.4% over a week.
What factors affect Sanofi SA?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Sanofi SA, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Sanofi SA?
9 backtested tactical asset allocation strategies trade Sanofi SA through VGK; 1 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Sanofi SA returns analysed?
The Statistical Distribution of Returns section shows the distribution of Sanofi SA daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Sanofi SA historical data?
In the Free historical data section of this page: the last 10 years of Sanofi SA daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Sanofi SA historical data (last 10 years)

Browse or instantly download the last 10 years of Sanofi SA daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.SAN.PA&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-2084.92
2026-11-1983.79
2026-11-1886.25
2026-11-1786.56
2026-11-1688.32
2026-11-1387.6
2026-11-1287.98
2026-11-1186.61
2026-11-1085.95
2026-11-0985.76
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in Finland and Germany. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine. It has a collaboration and license agreement with Exscientia to develop small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab; and antibody collaboration with Regeneron Pharmaceuticals, Inc. to develop antibodies, such as Dupixent (dupilumab) as treatment for diseases driven by type 2 inflammation. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.